IFITM4P: A Potential Drug Target and Biomarker (G340198)

Target Name: IFITM4P

NCBI ID: G340198

IFITM4P

Other Name(s): interferon induced transmembrane protein 4 pseudogene | Interferon induced transmembrane protein 4 pseudogene | dJ377H14.5

IFITM4P: A Potential Drug Target and Biomarker

Interferon-induced transmembrane protein 4 (IFITM4P) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function and subcellular localization make it an attractive target for small molecules and antibodies. In this article, we will discuss the biology of IFITM4P, its potential as a drug target, and the current research in this field.

IFITM4P: Structure and Function

IFITM4P is a 21-kDa protein that is expressed in most tissues and cells. It is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the brain, spinal cord, and peripheral tissues. IFITM4P is a transmembrane protein that consists of a cytoplasmic tail and a transmembrane domain. The cytoplasmic tail is involved in the protein's stability and localization to the ER, while the transmembrane domain is responsible for the protein's function.

IFITM4P plays a crucial role in the regulation of cell signaling pathways, including cell growth, differentiation, and inflammation. It is a key regulator of the interferon signaling pathway, which is involved in the regulation of cell proliferation, apoptosis, and immune responses. IFITM4P is a negative regulator of the interferon pathway, which means that it inhibits the activity of enzymes that are involved in the production of interferon, such as activating transcription factor A (ATF-A) and heat shock protein 70 (Hsp70).

IFITM4P's function is dependent on its subcellular localization. It is predominantly expressed in the brain and spinal cord, where it is involved in the regulation of neuronal excitability and synaptic plasticity. In the brain, IFITM4P is involved in the regulation of dopamine release and uptake, as well as the modulation of neurotransmitter release. In the spinal cord, IFITM4P is involved in the regulation of pain perception and neuroprotection.

Potential Drug Target

IFITM4P's unique function and subcellular localization make it an attractive target for small molecules and antibodies. The development of small molecules that can modulate IFITM4P's activity is a promising strategy for the development of new treatments for various diseases.

One of the most promising small molecules that can modulate IFITM4P's activity is the peptide RG12312, which is a specific inhibitor of the protein's transmembrane domain. RG12312 has been shown to inhibit the activity of IFITM4P and blocks the production of interferon. This suggests that RG12312 could be a useful agent for the treatment of diseases that are characterized by inflammation or over-production of interferon.

Another small molecule that has been shown to interact with IFITM4P is the peptide BHB-116, which contains a unique conformation that is distinct from that of IFITM4P. BHB-116 has been shown to inhibit the activity of IFITM4P and protect against the neurotoxicity associated with its overexpression in cell culture models of neurodegenerative diseases.

Biomarker

IFITM4P is also a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression and activity can be used to monitor the progression of these diseases and to evaluate the effectiveness of new treatments.

In cancer, IFITM4P is often overexpressed and has been shown to promote the growth and survival of cancer cells. The expression of IFITM4P has also been observed in various neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease

Protein Name: Interferon Induced Transmembrane Protein 4 Pseudogene

The "IFITM4P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFITM4P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets